Receptors and Channels Targeted by Synthetic Cannabinoid Receptor Agonists and Antagonists

Research output: Contribution to journalLiterature review

181 Citations (Scopus)

Abstract

It is widely accepted that non-endogenous compounds that target CB1 and/or CB2 receptors possess therapeutic potential for the clinical management of an ever growing number of disorders. Just a few of these disorders are already treated with Delta(9)-tetrahydrocannabinol or nabilone, both CB1/CB2 receptor agonists, and there is now considerable interest in expanding the clinical applications of such agonists and also in exploiting CB2-selective agonists, peripherally restricted CB1/CB2 receptor agonists and CB1/CB2 antagonists and inverse agonists as medicines. Already, numerous cannabinoid receptor ligands have been developed and their interactions with CB1 and CB2 receptors well characterized. This review describes what is currently known about the ability of such compounds to bind to, activate, inhibit or block non-CB1, nonCB(2) G protein-coupled receptors such as GPR55, transmitter gated channels, ion channels and nuclear receptors in an orthosteric or allosteric manner. It begins with a brief description of how each of these ligands interacts with CB1 and/or CB2 receptors.

Original languageEnglish
Pages (from-to)1360-1381
Number of pages22
JournalCurrent Medicinal Chemistry
Volume17
Issue number14
Publication statusPublished - 2010

Keywords

  • delta(9)-tetrahydrocannabinol
  • rimonabant
  • AM251
  • cannabinoid receptors
  • GPR55
  • G protein-coupled receptors
  • transmitter gated and ion channels
  • the nuclear receptors
  • PPAR alpha
  • PPAR gamma
  • trigeminal sensory neurons
  • food-reinforced behavior
  • mesenteric arterial bed
  • T-tubule membranes
  • CB2 receptor
  • in-vivo
  • calcium-channels
  • vanilloid receptors
  • independent actions
  • glycine receptors
  • ¿9-tetrahydrocannabinol
  • PPARa
  • PPAR¿

Cite this

Receptors and Channels Targeted by Synthetic Cannabinoid Receptor Agonists and Antagonists. / Pertwee, Roger Guy.

In: Current Medicinal Chemistry, Vol. 17, No. 14, 2010, p. 1360-1381.

Research output: Contribution to journalLiterature review

@article{e083aae474584b788ce0ff22dc545171,
title = "Receptors and Channels Targeted by Synthetic Cannabinoid Receptor Agonists and Antagonists",
abstract = "It is widely accepted that non-endogenous compounds that target CB1 and/or CB2 receptors possess therapeutic potential for the clinical management of an ever growing number of disorders. Just a few of these disorders are already treated with Delta(9)-tetrahydrocannabinol or nabilone, both CB1/CB2 receptor agonists, and there is now considerable interest in expanding the clinical applications of such agonists and also in exploiting CB2-selective agonists, peripherally restricted CB1/CB2 receptor agonists and CB1/CB2 antagonists and inverse agonists as medicines. Already, numerous cannabinoid receptor ligands have been developed and their interactions with CB1 and CB2 receptors well characterized. This review describes what is currently known about the ability of such compounds to bind to, activate, inhibit or block non-CB1, nonCB(2) G protein-coupled receptors such as GPR55, transmitter gated channels, ion channels and nuclear receptors in an orthosteric or allosteric manner. It begins with a brief description of how each of these ligands interacts with CB1 and/or CB2 receptors.",
keywords = "delta(9)-tetrahydrocannabinol, rimonabant, AM251, cannabinoid receptors, GPR55, G protein-coupled receptors, transmitter gated and ion channels, the nuclear receptors, PPAR alpha, PPAR gamma, trigeminal sensory neurons, food-reinforced behavior, mesenteric arterial bed, T-tubule membranes, CB2 receptor, in-vivo, calcium-channels, vanilloid receptors, independent actions, glycine receptors, ¿9-tetrahydrocannabinol, PPARa, PPAR¿",
author = "Pertwee, {Roger Guy}",
year = "2010",
language = "English",
volume = "17",
pages = "1360--1381",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "14",

}

TY - JOUR

T1 - Receptors and Channels Targeted by Synthetic Cannabinoid Receptor Agonists and Antagonists

AU - Pertwee, Roger Guy

PY - 2010

Y1 - 2010

N2 - It is widely accepted that non-endogenous compounds that target CB1 and/or CB2 receptors possess therapeutic potential for the clinical management of an ever growing number of disorders. Just a few of these disorders are already treated with Delta(9)-tetrahydrocannabinol or nabilone, both CB1/CB2 receptor agonists, and there is now considerable interest in expanding the clinical applications of such agonists and also in exploiting CB2-selective agonists, peripherally restricted CB1/CB2 receptor agonists and CB1/CB2 antagonists and inverse agonists as medicines. Already, numerous cannabinoid receptor ligands have been developed and their interactions with CB1 and CB2 receptors well characterized. This review describes what is currently known about the ability of such compounds to bind to, activate, inhibit or block non-CB1, nonCB(2) G protein-coupled receptors such as GPR55, transmitter gated channels, ion channels and nuclear receptors in an orthosteric or allosteric manner. It begins with a brief description of how each of these ligands interacts with CB1 and/or CB2 receptors.

AB - It is widely accepted that non-endogenous compounds that target CB1 and/or CB2 receptors possess therapeutic potential for the clinical management of an ever growing number of disorders. Just a few of these disorders are already treated with Delta(9)-tetrahydrocannabinol or nabilone, both CB1/CB2 receptor agonists, and there is now considerable interest in expanding the clinical applications of such agonists and also in exploiting CB2-selective agonists, peripherally restricted CB1/CB2 receptor agonists and CB1/CB2 antagonists and inverse agonists as medicines. Already, numerous cannabinoid receptor ligands have been developed and their interactions with CB1 and CB2 receptors well characterized. This review describes what is currently known about the ability of such compounds to bind to, activate, inhibit or block non-CB1, nonCB(2) G protein-coupled receptors such as GPR55, transmitter gated channels, ion channels and nuclear receptors in an orthosteric or allosteric manner. It begins with a brief description of how each of these ligands interacts with CB1 and/or CB2 receptors.

KW - delta(9)-tetrahydrocannabinol

KW - rimonabant

KW - AM251

KW - cannabinoid receptors

KW - GPR55

KW - G protein-coupled receptors

KW - transmitter gated and ion channels

KW - the nuclear receptors

KW - PPAR alpha

KW - PPAR gamma

KW - trigeminal sensory neurons

KW - food-reinforced behavior

KW - mesenteric arterial bed

KW - T-tubule membranes

KW - CB2 receptor

KW - in-vivo

KW - calcium-channels

KW - vanilloid receptors

KW - independent actions

KW - glycine receptors

KW - ¿9-tetrahydrocannabinol

KW - PPARa

KW - PPAR¿

M3 - Literature review

VL - 17

SP - 1360

EP - 1381

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 14

ER -